Search the Newsreel

Aardvark Therapeutics (NASDAQ:AARD) Releases Quarterly Earnings Results, Beats Expectations By $0.21 EPS

Aardvark Therapeutics (NASDAQ:AARD) announced its quarterly earnings, reporting a loss of $0.66 per share, which surpassed analyst expectations of a $0.87 loss by $0.21. Despite beating estimates, the company's shares fell by 4.9% to $7.19 during Tuesday trading. Institutional investors have increased their stakes, …

Aardvark Therapeutics Reports Q2 2026 Results, Updates ARD-101 PWS Program and FDA Discussions

Aardvark Therapeutics announced its Q2 2026 financial results, reporting a net loss of $14.4 million and a cash position of $73.9 million, sufficient to fund operations into late 2027. The company is actively engaging with the FDA to resolve a clinical hold on its …

Aardvark to Assess Unblinded Prader-Willi Trial Data in Q3 2026

Aardvark Therapeutics reported its second-quarter 2026 financial results, revealing $73.9 million in cash and short-term investments, which is expected to fund operations into late 2027. The company is currently assessing unblinded Phase 3 HERO and OLE trial data for ARD-101 in Prader-Willi syndrome in …

Aardvark Therapeutics, Inc. Q2 2026: Net loss $14.4M, EPS $(0.66) — 10-Q Summary

Aardvark Therapeutics, Inc. reported a net loss of $14.4 million, or $(0.66) per diluted share, for Q2 2026, consistent with the prior year. Cash and cash equivalents increased to $73.8 million. Clinical trials for ARD-101 and ARD-201 were paused due to cardiac observations, leading …

JHS Svendgaard turns profitable in Q1FY26 on revenue surge

JHS Svendgaard Laboratories Q1 Results: Net profit turns positive at ₹109 lakh

Aarti Pharmalabs Hits ₹868 Bull Target; Gains 15.6%

Defender Capital LLC. Has $12.37 Million Position in STAAR Surgical Company $STAA

Defender Capital LLC. reduced its stake in STAAR Surgical Company (NASDAQ:STAA) by 33.1% in the second quarter, now holding 431,187 shares valued at $12.37 million, which represents 4% of its portfolio. STAAR Surgical reported strong Q2 earnings, beating analyst expectations with EPS of $0.10 …

AARTIPHARM Standalone June 2026 Net Sales at Rs 534.59 crore, up 42.44% Y-o-Y

Aarti Pharmalabs shares rally over 33% in two days post Q1 results. What is driving the surge?

Aartech Solonics Q1 Results: Analyst call scheduled for Aug 14

What To Expect From STAAR Surgical’s (STAA) Q2 Earnings

STAAR Surgical (STAA) is set to report its Q2 earnings this Wednesday after market hours. Analysts expect a 104% year-on-year revenue growth, a significant reversal from the previous year's decline. Despite past revenue misses, analysts have reconfirmed their estimates, though STAA's share price has …

Aaron Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Are You Looking for a Top Momentum Pick? Why AAR (AIR) is a Great Choice

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

Astral Resources (ASX:AAR) Rises As Theia Drilling Builds Gold Momentum

Kwality Pharma, Aarti Pharmalabs, Universal Cables hit 20% upper circuits

Aarti Pharmalabs Q1 Results: Consolidated Net Profit Rises 65% YoY

Aarti Pharmalabs Ltd leads gainers in 'A' group

Aarti Pharmalabs shares hit 20% upper circuit as Q1 net profit surges 65% YoY to Rs 76 crore

Aarti Pharmalabs hits the roof after Q1 PAT rises 65% YoY

Aaron Industries Limited (NSE:AARON) Passed Our Checks, And It's About To Pay A ₹0.50 Dividend

How Investors Are Reacting To STAAR Surgical (STAA) Formalizing Warren Foust’s CEO Role And Leadership Structure

STAAR Surgical (STAA) recently formalized Warren Foust's role as President, CEO, and director, with Deborah Andrews becoming Executive Vice President and CFO, solidifying a leadership structure that was previously interim. This move is seen as reinforcing investor confidence by consolidating control under a leader …

Oliver Luxxe Assets LLC Has $3.48 Million Position in AAR Corp. $AIR

Oliver Luxxe Assets LLC significantly reduced its stake in AAR Corp. ($AIR) by 38.1% in the second quarter, yet still holds 24,349 shares valued at $3.48 million. Institutional investors collectively own 90.74% of AAR stock, which recently surpassed analyst expectations with strong quarterly earnings …

Janus Henderson Group PLC Sells 82,283 Shares of STAAR Surgical Company $STAA

Aarti Pharmalabs Q1 Results: Consolidated revenue surges 118% YoY

Aarti Pharmalabs Publishes Q1 FY27 Financial Results in Newspapers

3 Reasons We’re Fans of AAR (AIR)

3 Reasons We're Fans of AAR (AIR) AAR currently trades at $143.07 and has been a dream stock for shareholders. It's returned 315% since August 2021, blowing past the S&P 500's 73.6% gain. The company has also beaten the index over the past six …

AAR (AIR) Stock May Be Above Fair Value Following Its 320% Run

AAR (AIR) stock has seen a 320% return over the past five years, leading to questions about its current valuation. The stock trades at a P/E ratio of 30.0x, which is below the industry average but above Simply Wall St's fair P/E of 25.9x, …

Price to sales forward of Emaar, The Economic City – TADAWUL:4220

AIR Price History for AAR Corp Stock

This article from Barchart.com provides a price history for AAR Corp (AIR) stock, detailing features for members to access and analyze historical data, including daily prices, latest trades, and corporate actions. It also highlights 52-week key points, including high and low prices, Fibonacci levels, …

Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a share - Earnings Preview

Aardvark Therapeutics, Inc. is projected to report a loss of 87 cents per share in its upcoming earnings. This information comes from a Refinitiv earnings preview. The full article content is accessible via TradingView, which provides news from various sources including Reuters.

Aarvi Encon Ltd. Earnings and Revenue – BSE:AARVI

Aarti Pharmalabs director Rajendra Gogri steps down

Form 8K STAAR Surgical Company For: 6 August By Investing.com

This article announces the filing of a Form 8K by STAAR Surgical Company on August 6th. The brief piece from Investing.com indicates that the Form 8K is publicly available for review. The publication also provides various market data and other news headlines.

Xaar plc 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:XAARF) 2026-08-07

STAAR Surgical (NASDAQ: STAA) names Warren Foust chief executive

STAAR Surgical has appointed Warren Foust as President and Chief Executive Officer, effective August 4, 2026. Foust previously served as Interim Co-CEO, President, and COO, and his compensation package includes a base salary of $730,000, a significant cash bonus target, and substantial equity grants …